Cisplatin has been the gold standard for treatment of Solid Tumors for the last 50 years.
However high toxicity profile of Cisplatin creates high degree of side effects that makes chemotherapy difficult for many of the patients. This also creates the need for the hospitalization of the cancer patients.
Liposomal Cisplatin with its targeted chemotherapy provides minimal side effects with no need for hospitalization.
The clinical studies that has been conducted with Liposomal Cisplatin has shown better quality of life but the superiority of Liposomal Cisplatin to Cisplatin could not be claimed.
Pharmacoeconomic benefits of Liposomal Cisplatin comes from almost no use of anti-emetics and no need for hospitalization.
With the Liposomal Technology Platform Lipotech expects to make new formulations like cream of Liposomal Cisplatin for early and late stage Melanoma patients.
The technology platform enables Lipotech to bring new Liposomal Oncology Drugs in years to come.